Titlebook: Cancer Immunology; Cancer Immunotherapy Nima Rezaei Book 20151st edition Springer-Verlag Berlin Heidelberg 2015 Cancer immunology.Cancer im

發(fā)出眩目光芒

包裹

Immunopathology of Head and Neck Tumors and Immunotherapy of Squamous Cell Carcinoma,nt treatment options and are held responsible for the initiation, metastasis, and recurrence of the disease. Thus, investigations on the interaction of CSCs with the host immune system have been performed, and targeting CSCs will potentially result in improved therapeutic outcome in the future.

intuition

Immunotherapy of Lung Tumors, with emphasis on humoral and cellular treatment modalities. Only recently, two monoclonal antibodies (mAbs), ipilimumab and nivolumab (BMS936558), have dramatically changed the outcome of melanoma treatments which were once almost nonexistent. In a dramatic analogy, these monoclonal antibodies seem

Arb853

懶惰民族

Fosfomycin in Cerebral and Spinal Abscesses,the immune response in vaccinated cancer patients was rarely associated with a significant clinical response. This chapter will discuss (a) the crucial issue of the most appropriate tumor antigens (self vs. mutated) to be used for vaccination in human solid tumors; (b) the different factors that may

Flat-Feet

繁忙

R. Achatzy,F. Daschner,N. Pittlik,F. Bartels remain elusive. There has been an increased appreciation of the critical role host immunity plays in the evolution of disease and the potential therapeutic efficacy of immune-based therapies. These treatment approaches hold the potential promise of selective targeting of the malignant clone, disrup

Asperity

B. Roth,G. Mattarelli,F. Bartelsoliferation, and resistance to apoptosis. It is now generally accepted that AML originates from genetic alterations in normal hematopoietic stem cells (HSC) or common myeloid progenitor cells, giving rise to the leukemic stem cell (LSC), from which the bulk of leukemic blasts arise, ultimately leadi

拔出

R. Achatzy,F. Daschner,N. Pittlik,F. Bartelsas targets for immunotherapy. Since CD20 is expressed in B-ALL cells, rituximab, an anti-CD20 antibody used in B-cell non-Hodgkin’s lymphomas (B-NHLs), has also been used in the ALL. Reports have shown that the addition of CD20 antibodies to conventional chemotherapy leads to a higher rate of comple

DAFT

https://doi.org/10.1007/978-1-0716-4019-7other treatment modalities in the treatment of Hodgkin lymphoma (HL), attention has been drawn to immunotherapy as an efficient alternative or complement therapy. This chapter seeks to discuss a wide spectrum of immunotherapeutic approaches, from initial monoclonal antibodies to novel techniques dev